Literature DB >> 21355073

Analysis of the oxidative damage repair genes NUDT1, OGG1, and MUTYH in patients from mismatch repair proficient HNPCC families (MSS-HNPCC).

Pilar Garre1, Verónica Briceño, Rosa M Xicola, Brian J Doyle, Miguel de la Hoya, Julián Sanz, Patricia Llovet, Paula Pescador, Javier Puente, Eduardo Díaz-Rubio, Xavier Llor, Trinidad Caldés.   

Abstract

PURPOSE: Several studies have described molecular differences between microsatellite stable hereditary nonpolyposis colorectal cancer (MSS-HNPCC) and microsatellite unstable Lynch syndrome tumors (MSI-HNPCC). These differences highlight the possibility that other instability forms could explain cancer susceptibility in this group of families. The base excision repair (BER) pathway is the major DNA repair pathway for oxidative DNA damage. A defect in this pathway can result in DNA transversion mutations and a subsequent increased cancer risk. Mutations in MUTYH have been associated with increased colorectal cancer (CRC) risk while no association has been described for OGG1 or NUDT1. EXPERIMENTAL
DESIGN: We performed mutational screening of the three genes involved in defense against oxidative DNA damage in a set of 42 MSS-HNPCC families.
RESULTS: Eight rare variants and 5 frequent variants were found in MSS-HNPCC patients. All variants were previously described by other authors except variant c.285C>T in OGG1. Segregation studies were done and in silico programs were used to estimate the level of amino acid conservation, protein damage prediction, and possible splicing alterations. Variants OGG1 c.137G>A; MUTYH c.1187G>A were detected in Amsterdam I families and cosegregate with cancer. Analysis of OGG1 c.137G>A transcripts showed an inactivation of the splicing donor of exon 1.
CONCLUSIONS: Two rare variants (OGG1 c.137G>A; MUTYH c.1187G>A) and one common polymorphism (NUDT1 c.426C>T) were associated with CRC risk. We show that the BER pathway can play a significant role in a number of MSS-HNPCC colorectal cancers. More studies could be of interest in order to gain further understanding of yet unexplained CRC susceptibility cases.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21355073     DOI: 10.1158/1078-0432.CCR-10-2491

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  16 in total

1.  Differential expression profile analysis of DNA damage repair genes in CD133+/CD133- colorectal cancer cells.

Authors:  Yuhong Lu; Xin Zhou; Qingliang Zeng; Daishun Liu; Changwu Yue
Journal:  Oncol Lett       Date:  2017-06-19       Impact factor: 2.967

Review 2.  Genetic predisposition to colorectal cancer: where we stand and future perspectives.

Authors:  Laura Valle
Journal:  World J Gastroenterol       Date:  2014-08-07       Impact factor: 5.742

3.  Association of a let-7 miRNA binding region of TGFBR1 with hereditary mismatch repair proficient colorectal cancer (MSS HNPCC).

Authors:  Rosa M Xicola; Sneha Bontu; Brian J Doyle; Jamie Rawson; Pilar Garre; Esther Lee; Miguel de la Hoya; Xavier Bessa; Joan Clofent; Luis Bujanda; Francesc Balaguer; Sergi Castellví-Bel; Cristina Alenda; Rodrigo Jover; Clara Ruiz-Ponte; Sapna Syngal; Montserrat Andreu; Angel Carracedo; Antoni Castells; Polly A Newcomb; Noralane Lindor; John D Potter; John A Baron; Nathan A Ellis; Trinidad Caldes; Xavier LLor
Journal:  Carcinogenesis       Date:  2016-05-27       Impact factor: 4.944

4.  Targeting PIM Kinase with PD1 Inhibition Improves Immunotherapeutic Antitumor T-cell Response.

Authors:  Shilpak Chatterjee; Paramita Chakraborty; Anusara Daenthanasanmak; Supinya Iamsawat; Gabriela Andrejeva; Libia A Luevano; Melissa Wolf; Uday Baliga; Carsten Krieg; Craig C Beeson; Meenal Mehrotra; Elizabeth G Hill; Jeffery C Rathmell; Xue-Zhong Yu; Andrew S Kraft; Shikhar Mehrotra
Journal:  Clin Cancer Res       Date:  2018-10-16       Impact factor: 12.531

5.  Substitution mutational signatures in whole-genome-sequenced cancers in the UK population.

Authors:  Andrea Degasperi; Xueqing Zou; Tauanne Dias Amarante; Andrea Martinez-Martinez; Gene Ching Chiek Koh; João M L Dias; Laura Heskin; Lucia Chmelova; Giuseppe Rinaldi; Valerie Ya Wen Wang; Arjun S Nanda; Aaron Bernstein; Sophie E Momen; Jamie Young; Daniel Perez-Gil; Yasin Memari; Cherif Badja; Scott Shooter; Jan Czarnecki; Matthew A Brown; Helen R Davies; Serena Nik-Zainal
Journal:  Science       Date:  2022-04-22       Impact factor: 63.714

6.  NUDT expression is predictive of prognosis in patients with clear cell renal cell carcinoma.

Authors:  Yue Wang; Fangning Wan; Kun Chang; Xiaolin Lu; Bo Dai; Dingwei Ye
Journal:  Oncol Lett       Date:  2017-09-18       Impact factor: 2.967

7.  Association between polymorphisms of APE1 and OGG1 and risk of colorectal cancer in Taiwan.

Authors:  Ching-Yu Lai; Ling-Ling Hsieh; Reiping Tang; Regina M Santella; Chung Rong Chang-Chieh; Chih-Ching Yeh
Journal:  World J Gastroenterol       Date:  2016-03-28       Impact factor: 5.742

8.  Cancer risk and overall survival in mismatch repair proficient hereditary non-polyposis colorectal cancer, Lynch syndrome and sporadic colorectal cancer.

Authors:  Pilar Garre; Lorena Martín; Inmaculada Bando; Alicia Tosar; Patricia Llovet; Julián Sanz; Atocha Romero; Miguel de la Hoya; Eduardo Díaz-Rubio; Trinidad Caldés
Journal:  Fam Cancer       Date:  2014-03       Impact factor: 2.375

9.  APC and MUTYH Analysis in FAP Patients: A Novel Mutation in APC Gene and Genotype-Phenotype Correlation.

Authors:  Giovanna D'Elia; Gemma Caliendo; Amelia Casamassimi; Michele Cioffi; Anna Maria Molinari; Maria Teresa Vietri
Journal:  Genes (Basel)       Date:  2018-06-27       Impact factor: 4.096

10.  Inhibition of β2-microglobulin/hemochromatosis enhances radiation sensitivity by induction of iron overload in prostate cancer cells.

Authors:  Sajni Josson; Yasuhiro Matsuoka; Murali Gururajan; Takeo Nomura; Wen-Chin Huang; Xiaojian Yang; Jin-Tai Lin; Roger Bridgman; Chia-Yi Chu; Peter A Johnstone; Majd Zayzafoon; Peizhen Hu; Haiyen Zhau; Dror Berel; Andre Rogatko; Leland W K Chung
Journal:  PLoS One       Date:  2013-07-10       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.